CME/CE - PACE-CME

17-32 of 107

Potassium Binders in Practice: Clinical Trial Evidence
Potassium Binders in Practice: Clinical Trial Evidence
MinuteCE®
Potassium Binders in Practice: Clinical Trial Evidence
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Potassium Binders: Safety Comes First!
Potassium Binders: Safety Comes First!
MinuteCE®
Potassium Binders: Safety Comes First!
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
MinuteCE®
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
MinuteCE®
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
1.00 program credit
- James Burton, DM, FRCP
- Patrick Rossignol, MD, PhD
1.00 program credit
Future Directions in Managing Hyperkalemia in CKD and HF
Future Directions in Managing Hyperkalemia in CKD and HF
MinuteCE®
Future Directions in Managing Hyperkalemia in CKD and HF
1.00 program credit
- Javed Butler, MD, MPH, MBA
- James Burton, DM, FRCP
1.00 program credit
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
CME/CE
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
CME/CE
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
- Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
CME/CE
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
CME/CE
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
CME/CE
Expert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection
1.00 credit
- Muthiah Vaduganathan, MD, MPH
- Anuradha Lala-Trindade, MD
- Brendon Neuen, MBBS, PhD
1.00 credit
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits
Albuminuria Change and Finerenone's Effect on CV Outcomes
Albuminuria Change and Finerenone's Effect on CV Outcomes
DataPulse: Key Clinical Trial Insights on Nonsteroidal MRAs in CKM Syndrome Management
Albuminuria Change and Finerenone's Effect on CV Outcomes
- Finnian R. McCausland, MD
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
CME/CE
Nonsteroidal MRA & SGLT2i in People With CKD & T2D: Current Evidence and Rationale for Combination Therapy
0.25 credits
- prof. Hiddo Heerspink
- Jennifer B. Green, MD
0.25 credits
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
CME/CE
Practical Strategies for Optimizing Outcomes in Patients with Iron Deficiency and Heart Failure
0.25 credits
- Robert J. Mentz, MD, FHFSA, FACC, FAHA
- Piotr Ponikowski, MD, PhD, FESC, FHFA
0.25 credits

2/7